Most commonly rheumatic, though history of acute rheumatic fever is now uncommon; rare causes include congenital MS and severe calcification of the mitral annulus with extension onto the leaflets.
Symptoms most commonly begin in the fourth decade, but MS often causes severe disability at earlier ages in developing nations. Principal symptoms are dyspnea and cough precipitated by exertion, excitement, fever, anemia, tachycardia, pregnancy, sexual intercourse, and thyrotoxicosis.
Right ventricular lift; palpable S1; opening snap (OS) follows A2 by 0.05-0.12 s; OS-A2 interval inversely proportional to severity of obstruction. Diastolic rumbling murmur, best heard at apex in left lateral decubitus position, with presystolic accentuation when in sinus rhythm. Duration of murmur correlates with severity of obstruction.
Hemoptysis, pulmonary embolism, respiratory infections, systemic embolization; endocarditis is uncommon in pure MS.
Typically shows atrial fibrillation (AF) or left atrial (LA) enlargement when sinus rhythm is present. Right-axis deviation and RV hypertrophy in the presence of pulmonary hypertension.
Shows reduced separation, thickening and calcification of mitral leaflets and subvalvular apparatus, LA enlargement. Doppler assessment provides estimation of transvalvular peak and mean gradients, mitral valve area, and degree of pulmonary hypertension (Chap. 114 Noninvasive Examination of the Heart).
TREATMENT | ||
Mitral StenosisAt-risk pts should receive prophylaxis for recurrent rheumatic fever (penicillin V 250-500 mg PO bid or benzathine penicillin G 1-2 M units IM monthly) (see Fig. 116-1. Management of Rheumatic Mitral Stenosis). For dyspnea, prescribe sodium restriction and oral diuretic therapy; beta blockers, rate-limiting calcium channel antagonists (i.e., verapamil or diltiazem), or digoxin are used to slow ventricular rate in AF. Warfarin (with target INR 2.0-3.0) for pts with AF or history of thromboembolism (direct acting oral anticoagulants [DOACs, e.g., apixaban, rivaroxaban, dabigatran] are not approved for pts with rheumatic MS). For AF of recent onset, consider conversion (chemical or electrical) to sinus rhythm, ideally after ≥3 weeks of anticoagulation. Mitral valvotomy in the presence of symptoms and mitral orifice ≤∼1.5 cm2 . In uncomplicated MS, percutaneous balloon valvuloplasty is the procedure of choice; if not feasible, then open surgical valvotomy (Fig. 116-1. Management of Rheumatic Mitral Stenosis). |
Acute MR: Infective endocarditis, papillary muscle rupture post-MI, ruptured chordae tendineae. Chronic MR: Myxomatous deformity (mitral valve prolapse [MVP]), mitral annular calcification, rheumatic, healed endocarditis, congenital, radiation damage, LV enlargement of any cause, hypertrophic cardiomyopathy (with systolic anterior motion of anterior mitral leaflet).
Acute MR: Commonly presents with symptoms and signs of acute pulmonary edema. Chronic MR: Mild-moderate disease is typically asymptomatic. In chronic severe MR, fatigue, exertional dyspnea, orthopnea, palpitations are common, and physical examination shows sharp low-volume carotid upstroke, laterally displaced apical impulse, LV is hyperdynamic, S1 diminished, wide splitting of S2; S3 common; loud holosystolic murmur at the apex and often a brief early-mid-diastolic murmur due to increased transvalvular flow. Murmur typically radiates to axilla, but may radiate to base instead when due to prolapsing or flail posterior leaflet.
Often identifies mechanism of MR (TEE provides greater anatomic detail, when needed). Measures LA size and LV dimensions and contractile function, which are important to follow serially over time. Doppler techniques quantify severity of MR and provide estimate of pulmonary artery systolic pressure.
TREATMENT | ||
Mitral RegurgitationFor severe/decompensated MR, treat as for heart failure (Chap. 126 Heart Failure and Cor Pulmonale) (See Fig. 116-2. Management of Mitral Regurgitation). IV vasodilators (e.g., nitroprusside) are beneficial for acute, severe MR. Anticoagulation (warfarin, or a DOAC, in the absence of rheumatic MS or a mechanical prosthetic heart valve) is indicated if AF is present, as guided by the CHA2DS2-VASc risk score. For chronic, severe, primary MR, surgical valve repair or replacement is appropriate if pt has symptoms or progressive LV dysfunction (e.g., LV ejection fraction [LVEF] <60% or end-systolic LV diameter ≥40 mm). Operation should be carried out before development of chronic heart failure symptoms. Valve repair should also be considered for asymptomatic pts with severe chronic MR with recent onset AF, pulmonary hypertension (PA systolic pressure ≥50 mmHg at rest, or ≥60 mmHg with exercise), or a progressive decrease in LVEF, or increase in LV end-systolic diameter, on serial imaging. Pts with secondary MR due to ischemic disease may require coronary artery revascularization along with valve repair. For pts with secondary MR and significantly reduced LVEF (ischemic MR or MR due to LV enlargement/cardiomyopathy), the focus of therapy should be on aggressive guideline-directed nonsurgical therapy (Chap. 116 Valvular Heart Disease and Fig. 116-2. Management of Mitral Regurgitation), with invasive intervention reserved for refractory symptoms. Transcatheter mitral valve repair, using a clip to tether the mid-portion of the leaflet edges together, is commercially available for symptomatic pts with severe, primary (e.g., myxomatous) MR at very high or prohibitive surgical risk. |
Excessive/redundant mitral leaflet tissue typically of unknown cause; may also accompany certain connective tissue disorders, e.g., Marfan syndrome, Ehlers-Danlos syndrome.
Redundant mitral valve tissue often with myxedematous degeneration and increased glycosaminoglycans.
More common in females, most pts are asymptomatic. Yet MVP is the most common cause of primary MR ultimately requiring surgical treatment in North America. Potential symptoms include vague chest discomforts and supraventricular and ventricular arrhythmias. Most important complication is progressive MR. Rarely, systemic emboli from platelet-fibrin deposits on valve lead to transient ischemic attacks. Sudden death is a very rare outcome of MVP.
Mid or late systolic click(s) followed by high-pitched late systolic murmur at the apex (radiates to axilla with anterior leaflet prolapse, often to base with posterior leaflet prolapse). Click and murmur move earlier and are exaggerated by Valsalva maneuver; they are delayed and softened by squatting and isometric exercise (Chap. 112 Physical Examination of the Heart).
Shows posterior displacement of one or both mitral leaflets late in systole. Doppler techniques assess severity of accompanying MR. 3-D echo or magnetic reasonance imaging are sometimes used to precisely determine LV volumes.
TREATMENT | ||
Mitral Valve ProlapseAsymptomatic pts should be reassured. Beta blockers may lessen chest discomfort and palpitations. Prophylaxis for infective endocarditis is indicated only if prior history of endocarditis. Valve repair or replacement indicated for pts with severe MR who are symptomatic or show progressive LV systolic dysfunction, recent onset AF, or pulmonary hypertension. |
Most common: (1) degenerative calcification of a congenitally bicuspid valve, (2) chronic deterioration and calcification of a trileaflet valve, and (3) rheumatic disease (almost always associated with rheumatic mitral disease).
Exertional dyspnea, angina, and syncope are cardinal symptoms; they occur late, after years of obstruction and aortic valve area ≤1.0 cm2 .
Weak and delayed (parvus et tardus) arterial pulses with carotid thrill. A2 soft or absent; S4 common. Crescendo-decrescendo systolic murmur, often with systolic thrill. Murmur is typically loudest at second right intercostal space, with radiation to carotids and sometimes to the apex (Gallavardin effect).
Identifies LV hypertrophy, calcification and thickening of aortic valve cusps with reduced systolic opening, and any accompanying enlargement of aortic root and/or ascending aorta. Dilatation of LV and impaired contraction indicate poor prognosis. Doppler quantitates systolic gradient and allows calculation of valve area. Dobutamine stress echocardiography is helpful to assess severity of AS when there is accompanying LV systolic dysfunction.
TREATMENT | ||
Aortic StenosisAvoid strenuous activity and hypovolemia/dehydration in severe AS (see Fig. 116-3. Algorithm for the Management of Aortic Stenosis (As)). Beta-blockers and ACE inhibitors are generally safe to use for treatment of hypertension and ischemic heart disease in the presence of normal systolic function. Valve replacement is most clearly indicated for adults with severe obstruction (valve area <1 cm2 ) and (1) symptoms resulting from AS, (2) those with LVEF <50%, or (3) if other cardiovascular surgery is planned. Transcatheter aortic valve replacement (TAVR) is an alternative approach with excellent results for pts at prohibitive, high, or intermediate surgical risk. TAVR is associated with early stroke hazard, and need for permanent pacemaker in ∼10% of pts. Post-procedure paravalvular aortic regurgitation (AR) is a major predictor of subsequent mortality. |
Valvular: Includes congenitally bicuspid valve, endocarditis, or rheumatic (especially if rheumatic mitral disease is present). Dilated aortic root: dilatation due to cystic medial necrosis, aortic dissection, ankylosing spondylitis, syphilis.
When chronic severe AR is symptomatic, manifests as awareness of forceful heartbeat, exertional dyspnea, and other signs of LV failure (orthopnea, paroxysmal nocturnal dyspnea) and sometimes angina pectoris. A widened pulse pressure, rapidly rising water hammer pulse, capillary pulsations (Quincke's sign), and a heaving, laterally displaced LV impulse are common. On auscultation A2 is soft or absent, an S3 may be present, and there is a high-pitched, blowing, decrescendo early diastolic murmur along the left sternal border (but often along right sternal border when AR is due to aortic dilatation). In acute severe AR, the pulse pressure is typically not widened and the diastolic murmur is often short and soft.
ECG: Signs of LV hypertrophy with strain. CXR: apex is displayed downward and to the left; aneurysmal dilatation of the aorta may be present.
LV enlargement, possible aortic dilatation, high-frequency diastolic fluttering of mitral valve. Failure of coaptation of aortic valve leaflets may be present. Doppler studies detect and quantify AR. Cardiac magnetic resonance imaging helpful for quantification of AR, LV contractile function, and aortic enlargement if echo is inadequate.
TREATMENT | ||
Aortic RegurgitationAcute severe AR requires intravenous diuretics and vasodilators (e.g., sodium nitroprusside) and usually early surgical correction. For chronic AR, vasodilators (ACE inhibitor or long-acting nifedipine) are recommended if hypertension present. Avoid beta blockers, which prolong diastolic filling. Surgical valve replacement should be considered in pts with chronic severe AR when symptoms develop or in asymptomatic pts with LV dysfunction (e.g., LVEF <50%, end-systolic diameter >50 mm, or LV diastolic dimension >65 mm) by imaging studies. |
Hepatomegaly, ascites, peripheral edema, jaundice, jugular venous distention with slow y descent (Chap. 112 Physical Examination of the Heart). Diastolic rumbling murmur along left sternal border increased by inspiration with loud presystolic component. ECG shows tall P waves in lead II (right atrial enlargement) without RV hypertrophy. Chest X-ray shows right atrial and superior vena caval enlargement. Doppler echocardiography demonstrates thickened valve and impaired separation of leaflets and provides estimate of transvalvular gradient.
TREATMENT | ||
Tricuspid StenosisIn severe TS (mean gradient >4 mmHg, valve area <1.5-2.0 cm2 ), surgical relief is indicated, with valvular repair or replacement. |
Usually functional and secondary to marked RV dilatation of any cause, often associated with pulmonary hypertension. Other causes include rheumatic disease, endocarditis, myxomatous valve disease, and carcinoid valvular disease.
RV failure, with edema, hepatomegaly, and prominent c-v waves in jugular venous pulse with rapid y descent (Chap. 112 Physical Examination of the Heart). Systolic murmur along lower left sternal edge is increased by inspiration. A prominent RV pulsation at left sternal edge may be present. Doppler echocardiography confirms diagnosis and estimates severity of disease.
TREATMENT | ||
Tricuspid RegurgitationIntensive diuretic therapy when right-sided heart failure signs are present. In severe cases surgical treatment consists of tricuspid annuloplasty or valve replacement. |
Symptoms occur only with severe disease (peak transvalvular gradient >50 mmHg) and include exertional dyspnea, fatigue, and occasionally angina, owing to RV oxygen demand. Physical findings include a crescendo-decrescendo systolic murmur at the second left interspace typically preceded by a systolic ejection click. A right-sided S4 may be present. A prominent a wave is typical in the jugular venous pulse. The ECG in severe PS shows right ventricular hypertrophy and right atrial enlargement. The chest x-ray shows right atrial and right ventricular enlargement; post-stenotic enlargement of the pulmonary artery may be present. Doppler echocardiography demonstrates the stenotic valve and quantitates the transvalvular gradient.
TREATMENT | ||
Pulmonic StenosisDiuretics for initial symptoms of right heart failure. Symptomatic pts with severe PS who have less than moderate pulmonic regurgitation are candidates for percutaneous balloon valvotomy; otherwise open surgery may be required. |